TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8872690
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg and Esmolol 2 mg/kg (Group LID-E2)
Study: 1504110
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg yohimbine orally
Study: 6096626
Drug: Etomidate (0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.26 mg/kg)
Study: 29074099
Drug: Long-acting pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting pasireotide (60 mg intramuscularly every 28 days)
Study: 29074099
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of long-acting pasireotide and everolimus
Study: 16643262
Drug: BASO II
Approvals — FDA: no, EMA: no, PMDA: no
Description: BASO II trial (treatment trial)
Study: 26685849
Drug: Amoxicillin/metronidazole for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/metronidazole for 7 days
Study: 23747646
Drug: Home-based treadmill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treadmill training (6 times per week, twice daily for 10-20 minutes, for 6 weeks)
Study: 20032102
Drug: rAAV2‐TNFR:Fc (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2‐TNFR:Fc (1 x 10(11), 1 x 10(12), or 1 x 10(13) DNase‐resistant particles/ml joint volume)
Study: 10759886
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with continuous intravenous infusion of antithrombin III and two intraperitoneal instillations of fresh frozen human donor serum
Study: 10759886
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with antithrombin III and serum
Study: 1639655
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy followed by local treatment and maintenance therapy
Study: 19047976
Drug: Metronidazole 250
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 250 mg q.i.d., amoxicilline 1 gr b.i.d. and PPI standard dose (MAO)
Study: 19047976
Drug: Tinidazole 500
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 500 mg b.i.d., amoxicilline 1 gr b.i.d. and PPI standard dose (TAO)
Study: 2865120
Drug: Metronidazole monotherapy
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole monotherapy
Study: 2865120
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cortisone, salazosulfapyridine and metronidazole
Study: 27432821
Drug: L-carnitine (990
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (990 mg twice daily) for 12 weeks
Study: 20228983
Drug: Ketoconazole tablet
Normalized name: Ketoconazole Tablets
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole tablet (200 mg per day for 14 days)
Study: 20228983
Drug: Topical ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoconazole 2% in orabase (applied twice daily)
Study: 20228983
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between ketoconazole tablet and topical ketoconazole
Study: 12785457
Drug: Tramadol 75
Normalized name: traMADol 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 75 mg plus acetaminophen 650 mg
Study: 12785457
Drug: Tramadol/acetaminophen combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen combination
Study: 9527091
Drug: Soluble vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble vascular cell adhesion molecule-1 (VCAM-1)
Study: 8703648
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) 100 mg
Study: 8703648
Drug: Local infusions
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infusions and/or systemic treatments
Study: 370109
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride (150 mg daily)
Study: 370109
Drug: Diazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (20 mg daily)
Study: 10648337
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg
Study: 1737074
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light treatment (2000‐3000 lux)
Study: 1737074
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light placebo control treatment
Study: 6093524
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g three times daily
Study: 27027655
Drug: 5-mg once-yearly
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mg once-yearly infusions of zoledronic acid
Study: 12443576
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy plus anisodamine
Study: 6749701
Drug: Isoaminile citrate
Normalized name: isoaminile citrate
DrugBank: Isoaminile (DB08944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoaminile citrate (40 mg, 3 x daily)
Study: 6749701
Drug: Chlophedianol hydrochloride
Normalized name: Chlophedianol hydrochloride
DrugBank: Clofedanol (DB04837)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlophedianol hydrochloride (20 mg, 3 x daily)
Study: 6749701
Drug: Chlophedianol hydrochloride
Normalized name: Chlophedianol hydrochloride
DrugBank: Clofedanol (DB04837)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlophedianol hydrochloride (20 mg)
Study: 6749701
Drug: Isoaminile citrate
Normalized name: isoaminile citrate
DrugBank: Isoaminile (DB08944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoaminile citrate (40 mg)
Study: 25716730
Drug: MMSC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMSC infusion after allo-BMT
Study: 1866755
Drug: Oral dextromethorphan
Normalized name: dextromethorphan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextromethorphan (60 mg q.i.d.) for 3 weeks
Study: 23525797
Drug: Complete disruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete disruption of TP53 function (combination of point mutations and/or del17p)
Study: 19698011
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with losartan 50 mg and hydrochlorothiazide 12.5 mg/day
Study: 19698011
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/day (control group)
Study: 14973803
Drug: Acupressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure treatment (n = 75)
Study: 31178422
Drug: macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: macitentan 10 mg once daily
Study: 22336903
Drug: 640 mg
Normalized name: glycerin 1640 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg anthocyanins daily
Study: 22132138
Drug: BIS-guided propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS-guided propofol infusion titrated to a BIS level of 65-75
Study: 18654005
Drug: Phase III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III cardiac rehabilitation program (exercise training, diet therapy, and weekly counseling for 6 months)
Study: 17054108
Drug: FEC-HD (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-HD (fluorouracil 750 mg/m(2) on Days 1 to 4, epirubicin 35 mg/m(2) on Days 2 to 4, cyclophosphamide 400 mg/m(2) on Days 2 to 4 for 4 cycles every 21 days) with lenograstim
Study: 17054108
Drug: FEC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 75 (fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), cyclophosphamide 500 mg/m(2) on Day 1 every 21 days for 4 cycles)
Study: 8694298
Drug: Propofol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.25 or 2.5 mg/kg
Study: 8694298
Drug: Eltanolone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone 0.5 or 1 mg/kg
Study: 1461627
Drug: Low-dose megestrol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose megestrol acetate (480 mg/day)
Study: 1461627
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate (960 mg/day)
Study: 6322207
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (10 to 40 mg per day) with hydrochlorothiazide (50 mg per day) and alpha-methyldopa (250 to 1000 mg per day if necessary)
Study: 6322207
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg per day) with propranolol (80 to 240 mg per day) and hydralazine (100 to 200 mg per day if necessary)
Study: 30855708
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (10 sessions, one daily)
Study: 30855708
Drug: Placebo rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rTMS treatment
Study: 29463150
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg prasugrel
Study: 24583820
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg i.v. dexamethasone
Study: 15653007
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous combined HRT (1 mg 17beta-estradiol plus 0.5 mg norethisterone acetate)
Study: 15653007
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined HRT (0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days)
Study: 12040969
Drug: Diclofenac effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac effervescent tablet (DIC-BT) 150 mg/d for 7 days
Study: 12040969
Drug: Diclofenac enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac enteric coated dragees (DIC-mrD) 150 mg/d for 7 days
Study: 12040969
Drug: Diclofenac dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dispersible tablets (DIC-DispT) 150 mg/d for 7 days
Study: 12040969
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1500 mg/d for 7 days (positive control)
Study: 9620500
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (CE) 100 mg i.v. (20 mL) at the beginning of the procedure and a second dose of CE (100 mg i.v.) just after reperfusion of the new graft.
Study: 9620500
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL of isotonic sodium chloride solution) at the beginning of the procedure and a second dose of placebo (20 mL of isotonic sodium chloride solution) just after reperfusion of the new graft.
Study: 2360542
Drug: New milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New milk product (860 mL)
Study: 2360542
Drug: Normal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal milk (1000 mL)
Study: 17265458
Drug: T2000 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2000 (400 mg)
Study: 17265458
Drug: T2000 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2000 (300 mg)
Study: 17265458
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of T2000 (800 mg daily)
Study: 12666946
Drug: 25% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% metronidazole dental gel applied subgingivally on days 0 and 7 as an adjunct to scaling and root planing (SRP)
Study: 7659916
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine solution using 50% dimethylsulfoxide as a vehicle
Study: 7659916
Drug: Similar solution
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar solution without cyclosporine
Study: 2891032
Drug: Antacids or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids or H2 blockers
Study: 29510649
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (100 mg)
Study: 27824633
Drug: Inositol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (6 to 18 g/day)
Study: 25749502
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/d for 5 days and then every third day (12 total doses) + darbopoietin α 40 mcg/wk for 4 weeks (GDP group)
Study: 25749502
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) + darbopoietin α (GDP group)
Study: 20403998
Drug: Celecoxib treatment
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib treatment (200 mg and 400 mg)
Study: 12456380
Drug: Intravenous montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous montelukast (7 or 14 mg)
Study: 10615075
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion of floxuridine plus systemic fluorouracil (with or without leucovorin)
Study: 10615075
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy alone (monotherapy)
Study: 1768058
Drug: Abrasio only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrasio only treatment
Study: 1768058
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose gestagen therapy recommended for patients with CGH and high PgR concentration
Study: 30368658
Drug: Tylerdipine 5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tylerdipine 5-30 mg (SAD study)
Study: 30368658
Drug: Tylerdipine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tylerdipine 10 or 20 mg (MAD study)
Study: 28664722
Drug: Drug consumption
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug consumption among adolescents
Study: 28664722
Drug: Designer drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Designer drug consumption
Study: 28664722
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about designer drugs
Study: 26407095
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (2 g/day)
Study: 23371457
Drug: Jitongning Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitongning Capsule
Study: 15042388
Drug: EECP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EECP therapy with 5000 IU heparin pretreatment (H group)
Study: 15042388
Drug: Conventional EECP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional EECP therapy (C group)
Study: 15042388
Drug: EECP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EECP therapy with heparin pretreatment (H group)
Study: 8166475
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment protocols
Study: 2844044
Drug: Rubber band
Normalized name: CLOSURE,RUBBER BAND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubber band ligation (RBL) + unprocessed bran (twice-daily intake for 18 months)
Study: 29573212
Drug: General medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medication use
Study: 29573212
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use by age
Study: 28707771
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vaginal progesterone daily from 18 to 34 weeks gestation
Study: 28707771
Drug: Placebo ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ovule daily from 18 to 34 weeks gestation
Study: 24408336
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg caffeine tablet
Study: 21176950
Drug: 440 mg
Normalized name: placebo 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 440 mg albendazole and 40 mg/kg praziquantel
Study: 21176950
Drug: 440 mg
Normalized name: placebo 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 440 mg albendazole
Study: 17165280
Drug: Leukotriene modifier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene modifier drugs
Study: 17165280
Drug: Leukotriene modifier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene modifier drugs in combination with systemic corticosteroids
Study: 11068974
Drug: TNS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNS + paroxetine (20 mg)
Study: 11068974
Drug: TNS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNS + paroxetine (40 mg)
Study: 11068974
Drug: TNS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNS + paroxetine (20 mg) (compliant participants)
Study: 11068974
Drug: TNS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNS + paroxetine (40 mg) (compliant participants)
Study: 8616547
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly follow-up of pulmonary rehabilitation after home rehabilitation (Group A)
Study: 8616547
Drug: Once monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once monthly follow-up of pulmonary rehabilitation after home rehabilitation (Group B)
Study: 1424417
Drug: Ketorolac by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac by titration
Study: 1424417
Drug: Ketorolac by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac by bolus injection
Study: 3916836
Drug: liposteroid (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposteroid (2.5 mg of dexamethasone)
Study: 3916836
Drug: Decadron (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decadron (3.3 mg of dexamethasone)
Study: 27593706
Drug: Omeprazole (OME)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OME) 20-60 mg daily
Study: 15342613
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg etoricoxib alone and following daily doses of 400 mg ketoconazole
Study: 15342613
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg etoricoxib alone and following daily doses of 600 mg rifampin
Study: 15342613
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg etoricoxib once daily for 11 days
Study: 8074755
Drug: Albendazole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (three 400‐mg doses)
Study: 2899357
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of local anesthetic (bupivacaine or cocaine)
Study: 29797800
Drug: 6-month lifestyle
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month lifestyle intervention alongside CPAP treatment
Study: 22588361
Drug: Placebo (flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (flour capsule)
Study: 20634084
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of autologous platelet-rich plasma
Study: 16652216
Drug: Hiberix (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hiberix (booster dose)
Study: 16652216
Drug: Hiberix and
Normalized name: Hiberix
DrugBank: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (DB10990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hiberix and Infanrix‐DTPa (booster dose)
Study: 10853207
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms/kg plus dexamethasone 8 mg intravenously
Study: 8339858
Drug: Ponalrestat (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponalrestat (600 mg per day for 3 months)
Study: 3522040
Drug: metrizamide 240
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metrizamide 240 mg I/ml
Study: 29234966
Drug: Collaborative multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative multidisciplinary program for antibiotic prophylaxis
Study: 24786013
Drug: Orally soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally soluble film (OSF) of 50 mg sildenafil
Study: 24786013
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (FCT) of 50 mg sildenafil
Study: 18334811
Drug: Iscador M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador M 5 mg spezial (IM spez)
Study: 10078556
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (20 IU H-Insulin 100 Hoechst)
Study: 10078556
Drug: Vehicle (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (2.7 mg/ml m-Cresol)
Study: 7851587
Drug: Low-dose GnRH-a
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GnRH-a (250 micrograms SC leuprolide acetate) and hMG with elevated LH (> 35 mIU/mL)